0A8L

LSE:0A8L UK
Market Cap
$231.12K
Market Cap Rank
#21931 Global
#400 in UK
Share Price
$24.00
Change (1 day)
+60.00%
52-Week Range
$10.02 - $27.00
All Time High
$27.00
About

OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It also provides laboratory services; collaboration services, includ… Read more

0A8L (0A8L) - Net Assets

Latest net assets as of : $- USD

Based on the latest financial reports, 0A8L (0A8L) has net assets worth $- USD as of .

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($-) and total liabilities ($-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $-
% of Total Assets 0%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

0A8L - Net Assets Trend (None–None)

This chart illustrates how 0A8L's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for 0A8L (None–None)

The table below shows the annual net assets of 0A8L from None to None.

Year Net Assets Change
No yearly data available.

Equity Component Analysis

This analysis shows how different components contribute to 0A8L's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • No equity composition insights available.

0A8L Competitors by Market Cap

The table below lists competitors of 0A8L ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in 0A8L's equity between the two most recent reporting periods.

Insufficient data available to analyze equity growth attribution.

Book Value vs Market Value Analysis

This analysis compares 0A8L's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Insufficient data available to analyze book value vs market value.

Capital Efficiency Dashboard

This dashboard shows how efficiently 0A8L utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Insufficient data available to analyze capital efficiency metrics.

Industry Comparison

This section compares 0A8L's net assets metrics with peer companies in the same industry.

Industry Context

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
0A8L (0A8L) $- N/A N/A $42.99 Million
Nyfosa AB (0A0K) $2.92 Billion 39.50% 2.88x $973.31 Million
High Templar Tech Limited (0A2T) $12.52 Billion 4.70% 0.13x $255.82 Million
Strategy Inc (0A7O) $51.04 Billion -7.54% 0.21x $40.17 Billion
NACON SASU (0A9N) $67.54 Million 15.85% 1.20x $7.64 Million
Antin Infrastructure Partners (0AA5) $23.79 Million 108.98% 1.09x $573.10 Million
Truecaller AB Series B (0AA7) $1.41 Billion 18.30% 0.20x $281.60 Million
Brockhaus Technologies AG (0AAW) $254.92 Million -6.23% 1.68x $74.40 Million
Hyloris Pharmaceuticals S.A. (0AB6) $48.06 Million -24.09% 0.32x $71.96 Million
Kalray S.A. (0ABT) $28.43 Million -41.56% 0.67x $33.84 Million
Webuild S.p.A. (0BJP) $1.43 Billion 10.29% 7.14x $1.13 Billion